Pharmasight
Sign inSee a worked packBook the bench
Ship · Unlearn.AI

Used digital twins in a Phase 2a trial to predict Alzheimer's progression (AD/PD Boston 2025

remyndShipUnlearn.AIdigital twins

Unlearn.AI builds AI-generated 'digital twins' of clinical-trial patients, formally qualified by the EMA and reviewed positively by the FDA for reducing control-arm size in real trials.

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.

Source

Published by Unlearn.AI on its own site — read the original case study on unlearn.ai ↗

More like this

Related use cases

  1. 01Partnered on ALS Digital Twin Group database for Phase 1/2 trial designTrace NeuroscienceUnlearn.AIShip
  2. 02Assessed digital twins for variance reduction/sample-size savings in Alzheimer's Phase 2 trial (AAIC 2024 posterAbbVieUnlearn.AIShip
  3. 03Digital twins as a new lens for interpreting biomarker trends (AD/PD Vienna 2025 presentationAbbVieUnlearn.AIShip
  4. 04Accelerated Alzheimer's trials using generative ML disease-progression forecasts (AAIC 2024 posterJ&JUnlearn.AIShip
  5. 05Evaluated digital-twins methodology using completed Alzheimer's Phase 2 data (AAIC 2022 presentationRocheUnlearn.AIShip
  6. 06Applied digital twins to improve confidence in early-stage ALS trials (2024 ALS/MND presentationProJenXUnlearn.AIShip